FIELD: biotechnology.
SUBSTANCE: invention relates to effect of KRAS gene mutations for susceptibility to chemotherapy, and can be used in prediction of therapeutic effect of chemotherapy. Method for predicting therapeutic effect of chemotherapy that uses an antitumour agent comprising α,α,α-trifluorothymidine and 5-chloro-6-(1-(2-iminopyrrolidinyl)methyl)uracil hydrochloride at a molar ratio of 1:0.5 on a colorectal cancer patient, comprising steps of: (1) detecting presence or absence of mutation of codon 12 and/or codon 13 of KRAS gene in a biological sample obtained from patient; and (2) predicting that patient is likely to sufficiently respond to chemotherapy, when KRAS gene mutation is detected in step (1).
EFFECT: higher efficiency of chemotherapy.
6 cl, 3 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTICANCER MEDICINE, CONTAINING α,α,α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR | 2006 |
|
RU2394581C2 |
| PREPARATION POTENTIATING RADIATION THERAPY | 2007 |
|
RU2435587C2 |
| METHOD OF TREATING PATIENTS WITH CANCER WITH SEVERE RENAL INSUFFICIENCY | 2017 |
|
RU2727598C2 |
| COMBINATION OF TRIFLURIDINE/TIPIRACIL HYDROCHLORIDE, ANTITUMOR PLATINUM COMPLEX, AND MODULATOR OF CONTROL POINTS OF IMMUNE RESPONSE | 2018 |
|
RU2778887C2 |
| ANTITUMOUR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE | 2014 |
|
RU2657604C2 |
| ORAL PHARMACEUTICAL COMPOSITION | 2013 |
|
RU2639473C2 |
| ANTICANCER RNA VACCINES | 2017 |
|
RU2768829C2 |
| L718 AND/OR L792 MUTANT INHIBITOR OF TREATMENT-RESISTANT EGFR | 2019 |
|
RU2809621C2 |
| COMBINATION THERAPY | 2013 |
|
RU2677245C2 |
| LOW-DOSE ANTITUMOR AGENT INCLUDING IRINOTECAN HYDROCHLORIDE HYDRATE | 2014 |
|
RU2668125C2 |
